Alhydrogel

BIOLOGICAL5 trials

Sponsors

PharmAthene UK Limited, National Institute of Allergy and Infectious Diseases (NIAID), University Hospital Tuebingen, Institut National de la Santé Et de la Recherche Médicale, France, University of Oxford

Conditions

Immune ResponseMalariaMalaria, AntepartumPlaguePlasmodium Falciparum Malaria

Phase 1

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

CompletedNCT00246467

PharmAthene UK LimitedPlague

Start: 2005-10-31End: 2007-04-30Updated: 2008-09-15

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

CompletedNCT00587249

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Malaria

Start: 2002-07-31End: 2005-07-31Updated: 2013-04-12

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

CompletedNCT02647489

University Hospital TuebingenMalaria, Antepartum

Start: 2016-05-31End: 2017-11-10Updated: 2018-06-26

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

CompletedNCT02658253

Institut National de la Santé Et de la Recherche Médicale, FranceMalaria

Start: 2016-01-31End: 2019-02-21Updated: 2025-12-04

Unknown Phase

KLH Challenge to Explore the Human Immune Response

University of OxfordImmune Response

Start: 2023-03-01End: 2024-02-29Target: 39Updated: 2023-05-25

Related Papers

Progress and Insights Toward an Effective Placental Malaria Vaccine.

2021-02-2529 citations

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.

2020-02-0495 citations

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

Clinical Infectious Diseases2019-01-03150 citations

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.

2017-01-2512 citations

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.

2008-02-0639 citations